OSTX Stock Forecast & Price Target

OS Therapies is a promising biopharmaceutical company focused on developing innovative treatments for solid tumors, particularly Osteosarcoma. With a strong pipeline of products, including OST-HER2 and OST-tADC, the company is well positioned to address the pressing need for new treatments for bone cancers in children and young adults. Regulatory milestones, such as the rolling review by the EMA and planned meetings with the FDA, EMA, and MHRA on the Phase 2b and confirmatory Phase 3 protocols, are potential catalysts for the stock, and the company's strong financials and regulatory designations provide a solid foundation for future success. Additional execution against regulatory milestones and successful approval in the U.S. could also lead to a non-dilutive financing opportunity. Overall, the company's strong science and regulatory positioning make it a compelling investment opportunity with the potential for significant growth in the future.

OS Therapies is faced with a significant regulatory hurdle in the near future, with the potential for delayed market access and added costs if the FDA does not approve their Phase 2b clinical and biomarker data by the planned Pre-BLA meeting in 2026. Additionally, the company is relying heavily on potential monetization of their PRV to secure necessary funding for future milestones and maintain financial stability. There is also ongoing pressure to deliver on clinical and regulatory execution, which will likely continue to drive the stock's negative sentiment until these goals are achieved.